WEST LAFAYETTE, IN, Eradivir a clinical-stage biotechnology company that harnesses the power of the immune system to target and treat disease, today announced the closing of a $10 million private financing round.
The investment will support continued clinical development of the company's lead antiviral therapeutic for influenza, EV25, and advancement of a second molecule, EV148, for the treatment of respiratory syncytial virus (RSV).
Eradivir is a privately held, clinical-stage biotechnology company that focuses the power of the immune system to target and treat viral infections and other diseases. Its proprietary BAiT platform (Bispecific Antigenic immuno-Therapy) combines the simplicity of small molecule therapies with the efficacy of antibody therapies to facilitate rapid and selective diseased cell destruction. Eradivir's lead antiviral therapeutic EV25 is currently in a Phase 2 challenge study for the treatment of influenza.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
